Seeking Alpha

UBS initiates Insmed (INSM +0.7%) at Buy with a $17.50 price target representing a 37% upside....

UBS initiates Insmed (INSM +0.7%) at Buy with a $17.50 price target representing a 37% upside. Arikace "has a solid chance of success in its primary indication of cystic fibrosis," analyst Matthew Harrison says, adding that the "underappreciated" non-tuberculous mycobacteria opportunity could be another growth catalyst going forward. (Previous: Arikace's NTM indication possibly more compelling than CF opportunity)
Comments (1)
  • Linda-Lou
    , contributor
    Comment (1) | Send Message
     
    Am an RN and have NTM.
    18 Jun 2013, 04:30 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|